116 related articles for article (PubMed ID: 16343230)
21. Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Hızlı D; Boran N; Yılmaz S; Turan T; Altınbaş SK; Celik B; Köse MF
Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):71-5. PubMed ID: 22480413
[TBL] [Abstract][Full Text] [Related]
22. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
23. Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands: A Population-Based Cohort Study.
van de Laar R; Kruitwagen RF; IntHout J; Zusterzeel PL; Van Gorp T; Massuger LF
Int J Gynecol Cancer; 2016 Feb; 26(2):268-75. PubMed ID: 26588237
[TBL] [Abstract][Full Text] [Related]
24. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
25. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
26. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
Jänicke F; Hölscher M; Kuhn W; von Hugo R; Pache L; Siewert JR; Graeff H
Cancer; 1992 Oct; 70(8):2129-36. PubMed ID: 1394042
[TBL] [Abstract][Full Text] [Related]
27. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction.
Tian WJ; Jiang R; Cheng X; Tang J; Xing Y; Zang RY
J Surg Oncol; 2010 Mar; 101(3):244-50. PubMed ID: 20112269
[TBL] [Abstract][Full Text] [Related]
28. Surgery for recurrent ovarian cancer: Options and limits.
Sehouli J; Grabowski JP
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():88-95. PubMed ID: 27865654
[TBL] [Abstract][Full Text] [Related]
29. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
30. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.
Eisenkop SM; Friedman RL; Spirtos NM
Cancer; 2000 Jan; 88(1):144-53. PubMed ID: 10618617
[TBL] [Abstract][Full Text] [Related]
31. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
[TBL] [Abstract][Full Text] [Related]
32. Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Boran N; Hizli D; Yilmaz S; Turan T; Celik B; Karabuk E; Isikdogan Z; Tulunay G; Kose MF
J Surg Oncol; 2012 Sep; 106(4):369-75. PubMed ID: 22441998
[TBL] [Abstract][Full Text] [Related]
33. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
[TBL] [Abstract][Full Text] [Related]
34. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
35. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of patients with advanced stage ovarian cancer with intestinal metastasis.
Kebapcı E; Gülseren V; Tuğmen C; Gökçü M; Solmaz U; Sert İ; Kocaer M; Özer M; Ölmez M; Sancı M
Ginekol Pol; 2017; 88(10):537-542. PubMed ID: 29192414
[TBL] [Abstract][Full Text] [Related]
37. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
38. Surgery for recurrent ovarian cancer.
Heitz F; du Bois A; Kurzeder C; Pfisterer J; Barinoff J; Grabowski J; Hilpert F; Mahner S; Harter P
Womens Health (Lond); 2011 Sep; 7(5):529-35. PubMed ID: 21879821
[TBL] [Abstract][Full Text] [Related]
39. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
[TBL] [Abstract][Full Text] [Related]
40. [Recurrent epithelial ovarian cancer].
Ding X; Lang J; Shen K
Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):30-2. PubMed ID: 11263170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
